Anne Kerber, M.D.

Anne Kerber serves as senior vice president, head of Cell Therapy Development at Bristol Myers Squibb and leads all clinical trial and late development activities of BMS’ cell therapy portfolio.

Anne is an experienced leader and drug developer, with particular expertise in cell therapies. Prior to BMS, she worked at Kite, a Gilead Company, as vice president, Clinical Development. During her tenure at Kite and BMS, she has brought several CAR-T assets across different hematologic malignancies from clinical development to regulatory approval. Before that, she held several leadership roles at Affimed overseeing the development of T- and NK-cell engagers.

Anne received her M.D. from Philipps University in Marburg, Germany and she is a board-certified hematologist/oncologist. She also holds a degree in Pharmaceutical Medicine from the University of Basel, Switzerland.